Cisen Pharmaceutical Co., Ltd. (SHA:603367)
China flag China · Delayed Price · Currency is CNY
12.77
-0.21 (-1.62%)
Nov 13, 2026, 3:00 PM CST

Cisen Pharmaceutical Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
3,3193,4273,9724,4514,0493,773
Other Revenue
17.5617.5610.0211.1416.839.62
3,3363,4453,9824,4624,0663,783
Revenue Growth
-6.37%-13.48%-10.77%9.74%7.50%2.95%
Cost of Revenue
1,6621,7341,8131,9131,8271,728
Gross Profit
1,6741,7112,1682,5502,2392,055
Selling, General & Admin
1,1221,1131,3671,6001,5441,455
Research & Development
266.44285.78342.64374.88335.17334.35
Other Operating Expenses
30.530.4218.0220.9755.3750.31
Operating Expenses
1,4271,4401,7241,9991,9481,841
Operating Income
247.21270.96444.59550.79291.2214.24
Interest Expense
-1.09-1.34-6.95-6.59-4.29-6.1
Interest & Investment Income
170.22156.08101.8785.75390.18
Currency Exchange Gain (Loss)
-0.79-0.790.540.55-0.32-0.62
Other Non Operating Income (Expenses)
-2.14-0.33.65-1.27-0.175.21
EBT Excluding Unusual Items
413.41424.61543.71629.19339.41302.91
Gain (Loss) on Sale of Investments
-35.2339.6810.53-10.37-3.12-6.09
Gain (Loss) on Sale of Assets
-1.14-0.71-0.140.590.970.27
Asset Writedown
40.82-0.66-0.63-27.790.01-0.04
Other Unusual Items
33.2733.2722.34.2428.9239.09
Pretax Income
451.13496.19575.77595.86366.19336.13
Income Tax Expense
59.9970.5860.8370.4313.922.23
Earnings From Continuing Operations
391.14425.62514.94525.43352.27333.9
Minority Interest in Earnings
-4.07-4.37-6.03-4.09-2.310.24
Net Income
387.08421.25508.91521.34349.96334.15
Net Income to Common
387.08421.25508.91521.34349.96334.15
Net Income Growth
-21.45%-17.22%-2.38%48.97%4.73%-23.85%
Shares Outstanding (Basic)
451453454453454452
Shares Outstanding (Diluted)
451453454453454452
Shares Change
-1.20%-0.31%0.23%-0.25%0.65%-0.18%
EPS (Basic)
0.860.931.121.150.770.74
EPS (Diluted)
0.860.931.121.150.770.74
EPS Growth
-20.50%-16.96%-2.61%49.35%4.05%-23.71%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
428.72401.61469.04433.53223.15182.58
Free Cash Flow Per Share
0.950.891.030.960.490.40
Dividend Per Share
0.3760.3480.4400.4360.3350.300
Dividend Growth
-7.84%-20.91%0.92%30.15%11.67%17.19%
Gross Margin
50.18%49.66%54.46%57.14%55.06%54.32%
Operating Margin
7.41%7.87%11.17%12.34%7.16%5.66%
Profit Margin
11.60%12.23%12.78%11.68%8.61%8.83%
Free Cash Flow Margin
12.85%11.66%11.78%9.71%5.49%4.83%
EBITDA
423.46466.28665.34781.54519.77432.08
EBITDA Margin
12.69%13.54%16.71%17.51%12.78%11.42%
D&A For EBITDA
176.25195.32220.74230.75228.57217.84
EBIT
247.21270.96444.59550.79291.2214.24
EBIT Margin
7.41%7.87%11.17%12.34%7.16%5.66%
Effective Tax Rate
13.30%14.22%10.56%11.82%3.80%0.66%
Revenue as Reported
3,3363,4453,9824,4624,0663,783
Advertising Expenses
-19.911.470.820.20.51